Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.

Generic Drugs Policy

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.

M & A Business Strategies

Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view. 

Innovation Research and Development Strategies

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register